Key Points
- Director Jeff Vacirca bought 31,050 shares of Caris Life Sciences on May 11 at an average price of $16.15, a purchase worth about $501,458. After the transaction, he owned 49,671 shares, boosting his stake by 166.75%.
- CAI shares rose 5.1% and opened at $16.76, with the stock trading well below its 52-week high of $42.50. The company’s market cap is about $4.74 billion.
- Caris Life Sciences recently reported better-than-expected quarterly results, posting EPS of $0.28 versus a $0.01 estimate and revenue of $292.89 million, up 125.4% year over year. Analysts currently rate the stock a Moderate Buy with a consensus price target of $27.56.
Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) Director Jeff Vacirca purchased 31,050 shares of the business's stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $16.15 per share, with a total value of $501,457.50. Following the completion of the acquisition, the director directly owned 49,671 shares of the company's stock, valued at $802,186.65. This represents a 166.75% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Caris Life Sciences Stock Up 5.1%
NASDAQ CAI opened at $16.76 on Wednesday. The stock has a market capitalization of $4.74 billion and a PE ratio of -2.20. Caris Life Sciences, Inc. has a 52-week low of $15.70 and a 52-week high of $42.50. The business's 50-day moving average price is $18.97. The company has a quick ratio of 7.35, a current ratio of 7.05 and a debt-to-equity ratio of 0.64.
Caris Life Sciences (NASDAQ:CAI - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.27. Caris Life Sciences had a net margin of 3.75% and a return on equity of 98.28%. The firm had revenue of $292.89 million during the quarter, compared to analysts' expectations of $281.00 million. During the same period in the prior year, the company posted ($1.73) earnings per share. The firm's revenue for the quarter was up 125.4% on a year-over-year basis. On average, equities research analysts expect that Caris Life Sciences, Inc. will post 0.08 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research firms recently weighed in on CAI. BTIG Research lowered their price target on Caris Life Sciences from $38.00 to $32.00 and set a "buy" rating on the stock in a report on Friday, May 8th. Citigroup lowered their price target on Caris Life Sciences from $35.00 to $28.00 and set a "buy" rating on the stock in a report on Friday, May 8th. Jefferies Financial Group began coverage on Caris Life Sciences in a report on Monday, April 13th. They issued a "buy" rating and a $28.00 price target on the stock. Weiss Ratings upgraded Caris Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday. Finally, Wall Street Zen cut Caris Life Sciences from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $27.56.
Get Our Latest Stock Analysis on CAI
Institutional Trading of Caris Life Sciences
Several hedge funds and other institutional investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its stake in Caris Life Sciences by 839.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company's stock worth $29,000 after acquiring an additional 1,469 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Caris Life Sciences in the 1st quarter worth approximately $492,000. Bank of New York Mellon Corp grew its stake in Caris Life Sciences by 359.6% in the 1st quarter. Bank of New York Mellon Corp now owns 231,661 shares of the company's stock worth $4,142,000 after acquiring an additional 181,258 shares during the period. Emerald Advisers LLC purchased a new stake in Caris Life Sciences in the 1st quarter worth approximately $186,000. Finally, Fifth Third Bancorp purchased a new stake in Caris Life Sciences in the 1st quarter worth approximately $31,000.
About Caris Life Sciences
(
Get Free Report)
Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.
Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
